The importance of Cytotoxic T-Cell (CTL) reponses during the course of intracellular infections has received a lot of attention during the past few decades. CTLs respond to epitopes presented by the Major Histocompatibility Complex (MHC) originating from intracellular proteins for which they have an appropriate T-Cell Receptor (TCR) for. This response is crucial for the control of pathogens such as Influenza, Hepatitis, HIV and others by destroying the cell in which the pathogen replicates. Due to the extreme polymorphism of MHC molecules, Computational Immunology techniques have been developed to detect potential MHC ligands and as a consequence, potential CTL epitopes. The polymorphism factor needs to be taken into account especially when concerning the design of vaccines with a CTL response component to maximize population coverage. Tools have been constructed that combine the predictions tools concerning major steps in this pathway, that is, proteasomal cleavage, Transporter associated with Antigen Presentation (TAP) affinity, Major Histocompatibility Complex (MHC) affinity and Immunogenicity. In this study, a novel method is developed to combine the different steps in the pathway, which includes the development of a novel TAP predictor. Furthermore, by using a BLOSUM-based score in conjunction with the epitope prediction results, a novel CTL epitopebased clustering method was developed. Two pathogens with major CTL epitope components, but vastly different mutation rates were chosen to infer whether the aforementioned methods can be used to detect potential CTL epitopes and group sequences together based on shared immunogenicity. / Dissertation (MSc)--University of Pretoria, 2011. / Bioinformatics and Computational Biology Unit / unrestricted

No description available.

The magnitude and effectiveness of CD8 response against intracellular pathogens is directed by survival and apoptotic signals that govern the fate of T cells. XIAP is a bona fide endogenous inhibitor of apoptotic signals. In this thesis, I have investigated the role of XIAP at various stages of CD8 T cell response. I used both in vivo and in vitro models to show that XIAP acts in a CD8 T cell extrinsic and intrinsic manner to regulate the expansion and contraction phases of the CD8 T cell response, respectively. During the expansion phase, XIAP prevents the cell death of APCs to promote APC-T cell interaction and cytokine release, which facilitates the proliferation and survival of activated T cells. During the contraction phase, XIAP functions in a cell-intrinsic fashion to inhibit the proapoptotic signals in the activated CD8 T cells to prolong the immune response. Finally, I also demonstrate that the expression of XIAP in T cells is critical for their differentiation in to memory subsets. Overall, I present that XIAP plays a critical role in generating an effective CD8 T cell immune response.

Activation of immunity to self-antigens is the goal in cancer immunotherapy, whereas blocking such responses is the goal in autoimmune disease. Thus, it is not surprising that investigation into cancer immunotherapy might also produce insights for the treatment of autoimmune disease. Heat shock protein, gp96, based therapies lead to the robust activation of CD8+ cytotoxic T cells that can slow tumor growth in 60-70% of mice, but only lead to the elimination of tumors in 30-40% of animals. The primary goal of the current studies was to understand why vaccination with a secreted gp96 vaccine was not efficacious in a larger proportion of animals, and identify combination therapies that enhanced the anti-tumor activity of gp96-Ig vaccination. It was found that in mice bearing established tumors, some mice responded well to vaccination with gp96-Ig, and that the induction of CD8+ T cells was found to correlate with tumor rejection; indicating that the proportion of mice that failed to reject tumors had established mechanisms of tumor-mediated suppression of anti-tumor immunity. The mechanism of this suppression was found to differ between various tumor models, so combination therapy sought to amplify CD8+ T cell responses directly, rather than by indirectly inhibiting suppressive factors induced by established tumors. It was found that antibody-based therapies leading to the stimulation of TNFRSF25, a powerful T cell co-stimulatory receptor, caused synergistic expansion of tumor-specific T cells when given in combination with gp96-Ig vaccination and led to enhanced rejection of multiple tumor types. Interestingly, TNFRSF25 agonistic antibodies were also found to directly stimulate the proliferation of natural CD4+FoxP3+ regulatory T cells. This activity was found to be beneficial in the prevention of allergic lung inflammation when administered prior to antigen challenge. These studies have therefore identified the conditions required for successful tumor elimination following gp96-Ig vaccination, and discovered that a TNFRSF25 agonistic antibody may be used to enhance anti-tumor immunity induced by gp96-Ig. These studies have also identified TNFRSF25 stimulation as the most powerful, and physiologically relevant, method to selectively induce Treg proliferation in vivo ever discovered, with important consequences for the treatment of autoimmune inflammation.

No description available.

The Mater Medical Research Institute proposes to undertake a Phase I clinical trial using CMRF-56 immunoselected blood dendritic cells (BDC) loaded with control and myeloma-associated tumour peptide antigens for the treatment of multiple myeloma (MM) patients with minimal residual disease. This thesis describes some of the fundamental pre-clinical in vitro experiments undertaken in preparation for this trial so as to maximise the potential of this vaccine to induce myeloma-specific immune responses. These experiments involved determining the parameters for optimal activation of the CMRF-56 immunoselected cell preparation and exploring the potential of novel myeloma peptide antigens to induce anti-myeloma cytotoxic T lymphocyte (CTL) responses. CMRF-56 immunoselected cell preparations, containing predominately myeloid BDC, monocytes and B cells, were prepared from both healthy donors and myeloma patients. Activation of this preparation with granulocyte macrophage colony stimulating factor (GM-CSF) was found to increase co-stimulatory molecule expression by and survival of BDC, improve peptide- and lysate-specific CTL induction, and, in combination with prostaglandin E2 (PGE2), improve chemokine-specific migration of BDC. Following optimisation of in vitro CTL generation protocols, GM-CSF activated CMRF-56 immunoselected cells were examined for their ability to induce myeloma-specific immunity. Using lysate from myeloma cell line U266 as an antigen source, a polyclonal T cell pool was generated within which peptide specific CTL recognising myeloma antigens Muc1, HM1.24/BST2, DKK-1 and CT-7/MAGE-C1 could be identified. Furthermore, GM-CSF activated CMRF-56 immunoselected cells pulsed with HLA-A*201 restricted peptides derived from Muc1, HM1.24/BST2 and CT-7/MAGE-C1 could induce CTL capable of lysing both peptide- and myeloma cell line targets in both healthy donors and myeloma patients. These results provide the first evidence of immunogenic HLA-A*201 restricted epitopes of novel myeloma antigen CT-7/MAGE-C1. The data collected in this study supports the application of GM-CSF activated CMRF-56 immunoselected cells loaded with defined myeloma peptide antigens for the therapeutic vaccination of MM patients with minimal residual disease.

The Mater Medical Research Institute proposes to undertake a Phase I clinical trial using CMRF-56 immunoselected blood dendritic cells (BDC) loaded with control and myeloma-associated tumour peptide antigens for the treatment of multiple myeloma (MM) patients with minimal residual disease. This thesis describes some of the fundamental pre-clinical in vitro experiments undertaken in preparation for this trial so as to maximise the potential of this vaccine to induce myeloma-specific immune responses. These experiments involved determining the parameters for optimal activation of the CMRF-56 immunoselected cell preparation and exploring the potential of novel myeloma peptide antigens to induce anti-myeloma cytotoxic T lymphocyte (CTL) responses. CMRF-56 immunoselected cell preparations, containing predominately myeloid BDC, monocytes and B cells, were prepared from both healthy donors and myeloma patients. Activation of this preparation with granulocyte macrophage colony stimulating factor (GM-CSF) was found to increase co-stimulatory molecule expression by and survival of BDC, improve peptide- and lysate-specific CTL induction, and, in combination with prostaglandin E2 (PGE2), improve chemokine-specific migration of BDC. Following optimisation of in vitro CTL generation protocols, GM-CSF activated CMRF-56 immunoselected cells were examined for their ability to induce myeloma-specific immunity. Using lysate from myeloma cell line U266 as an antigen source, a polyclonal T cell pool was generated within which peptide specific CTL recognising myeloma antigens Muc1, HM1.24/BST2, DKK-1 and CT-7/MAGE-C1 could be identified. Furthermore, GM-CSF activated CMRF-56 immunoselected cells pulsed with HLA-A*201 restricted peptides derived from Muc1, HM1.24/BST2 and CT-7/MAGE-C1 could induce CTL capable of lysing both peptide- and myeloma cell line targets in both healthy donors and myeloma patients. These results provide the first evidence of immunogenic HLA-A*201 restricted epitopes of novel myeloma antigen CT-7/MAGE-C1. The data collected in this study supports the application of GM-CSF activated CMRF-56 immunoselected cells loaded with defined myeloma peptide antigens for the therapeutic vaccination of MM patients with minimal residual disease.

No description available.

Introduction Tumour-infiltrating lymphocytes (TIL) are an important prognostic indicator in high-grade serous ovarian carcinoma (HGSC). Certain types of TIL (in particular CD8+ effector T cells) predict better outcomes, whereas others (most notably CD4+CD25+FoxP3+ regulatory T cells; Tregs) predict worse outcomes. An unconventional subset of CD8+FoxP3+ T cells has been reported to be involved in autoimmunity and in immune response to several cancers. While the functional significance of CD8+FoxP3+ TIL remains poorly understood, they were associated with effective anti-tumour responses in a murine tumour model. Hypothesis CD8+FoxP3+ TIL are present in a subset of cases of HGSC and correlate with a strong immune response and increased patient survival. Experimental Design Multi-colour immunohistochemistry (IHC) was performed on a cohort of 44 primary HGSC specimens to enumerate and locate CD8+FoxP3+ TIL in comparison to CD8+FoxP3- and CD8-FoxP3+ TIL. Triple-colour IHC methodology was developed to further assess the phenotype of CD8+FoxP3+ TIL, including the measurement of additional markers CD4 and CD25 (classical markers of Tregs), Ki-67 (a marker of proliferation), and TIA-1 (a marker of cytotoxic potential). Intraepithelial versus stromal location was determined by staining adjacent sections for the epithelial marker pan-cytokeratin. Survival analysis was performed using a cohort of 188 cases of HGSC. Multi-colour staining was resolved using the Nuance™ multispectral imaging system in conjunction with Metamorph™ software. Survival analysis was performed using Kaplan-Meier and log rank tests. Results CD8+FoxP3+ cells were found in 60% of 44 cases of HGSC, in variable proportions ranging from 0.2 - 7.9% of CD8+ TIL and 0.5 – 12.7% of FoxP3+ TIL. CD8+FoxP3+ TIL were found to be either CD4+ (38.8%) or CD4- (61.2%). The majority of CD8+FoxP3+ TIL were also found to be CD25-TIA-1+Ki-67-, more closely resembling their CD8+FoxP3- counterparts. CD8+FoxP3+ TIL were found mainly in intraepithelial regions and were positively associated with patient survival (progression free survival; P = 0.0396). Conclusions CD8+FoxP3+ TIL are a component of the host immune response to HGSC. They appear to have a non-proliferative effector phenotype, consistent with an active role in the anti-tumour response. CD8+FoxP3+ TIL are associated with increased patient survival. An improved understanding of this new TIL subset may inform future immunotherapeutic strategies for this challenging malignancy. / Graduate / 0982 / sarakost@hotmail.com

Submitted by Simone Souza (simonecgsouza@hotmail.com) on 2017-09-22T15:04:46Z No. of bitstreams: 1 DISS_2014_Samantha Soares Ourives.pdf: 1603897 bytes, checksum: 16aacb8659dc1e9902e5038014c2c0ac (MD5) / Approved for entry into archive by Jordan (jordanbiblio@gmail.com) on 2017-09-26T14:26:40Z (GMT) No. of bitstreams: 1 DISS_2014_Samantha Soares Ourives.pdf: 1603897 bytes, checksum: 16aacb8659dc1e9902e5038014c2c0ac (MD5) / Made available in DSpace on 2017-09-26T14:26:40Z (GMT). No. of bitstreams: 1 DISS_2014_Samantha Soares Ourives.pdf: 1603897 bytes, checksum: 16aacb8659dc1e9902e5038014c2c0ac (MD5) Previous issue date: 2014-04-25 / CNPq / A malária é uma das doenças parasitárias de maior importância global e é responsável pelas principais causas de morbidade e mortalidade nas áreas tropicais e subtropicais do mundo. Apesar dos esforços para o controle da infecção em diferentes áreas endêmicas, a malária continua em expansão, e as medidas tradicionais de controle da transmissão são pouco eficazes. A resposta imune na malária é complexa, e os mecanismos de ativação e regulação de linfócitos T e suas citocinas ainda são pouco compreendidos. O objetivo deste trabalho foi avaliar a correlação da parasitemia com o número de plaquetas e leucócitos, e identificar e quantificar as subpopulações específicas de células Th1, Th2, Th17 e Treg, durante a infecção por P. vivax. Avaliando a parasitemia e o número de plaquetas, foi verificado que existe correlação negativa (p<0,0005) entre esses parâmetros e que, dependendo da quantidade de parasitas, os pacientes com malária vivax apresentavam um maior grau de plaquetopenia (p<0,0001). Avaliando o número de parasitas e de leucócitos totais, foi verificada ausência de correlação entre esses parâmetros em pacientes com malária vivax. Além disso, também não foi detectada alteração no número de leucócitos totais quando comparado aos controles sadios. Posteriormente, foi realizada, por meio de citometria de fluxo, a identificação e quantificação das subpopulações de células T: Th1 (CD3+CD4+IFN-γ+), Th2 (CD3+CD4+IL4+), Th17 (CD3+CD4+IL-17+), Treg (CD4+CD25+CD127-) e citotóxica (CD3+CD8+), em pacientes com malária vivax e em controles sadios após cultura de linfócitos previamente isolados do sangue periférico, para verificar a alteração do número dessas subpopulações de linfócitos pela infecção por P. vivax. O percentual da citocina IL-10 também foi avaliado nas células Treg (CD4+CD25+CD127-IL-10+). Os indivíduos infectados por P. vivax apresentaram percentual de células T citotóxica e Th1 aumentadas. Já o percentual de células Th2, Th17 e Tregs não apresentaram diferenças entre os grupos. Porém, o percentual de células Treg que produziam a citocina IL-10 estava aumentado em pacientes com malária vivax, quando comparado aos controles sadios. Finalmente, a avaliação do número de células T CD4+ e T CD8+, indicou que não houve diferenças entre a proporção desses linfócitos em controles sadios e nem durante o processo infeccioso induzido por P. vivax. Em conclusão, pacientes com malária vivax apresentam um aumento no número de células T citotóxicas, Th1 e de células Treg (CD4+CD25+CD127-) produtoras de interleucina-10, indicando que a infecção por P. vivax ativa células específicas que podem participar na imunorregulação contra esse parasita. / Malaria is a parasitic disease of major global importance and is responsible for leading causes of morbidity and mortality in tropical and subtropical areas of the world. Despite efforts to control the infection in different endemic areas, malaria continues to expand, and the traditional transmission control measures are ineffective. The immune response in malaria is complex, and the mechanisms of activation and regulation of T lymphocytes and their cytokines are still poorly understood. The objective of this study was to evaluate the correlation of parasitemia with the number of platelets and leukocytes, and identify and quantify specific subpopulations of Th1, Th2, Th17 and Treg cells in infection by P. vivax. Evaluating the parasitemia and the number of platelets was verified that there is a negative correlation (p<0,0005) between these parameters and that, dependent of the number of parasites, vivax malaria patients showed higher degree of thrombocytopenia (p<0,0001). Evaluating the number of parasites and total leukocytes was observed no correlation between these parameters in patients with vivax malaria. Moreover, it was also not detected change in the number of total leukocytes when compared to healthy controls. Subsequently, was performed by flow cytometry, identification and quantification of T cell subsets: Th1 (CD3+CD4+IFN-γ+), Th2 (CD3+CD4+IL4+), Th17 (CD3+CD4+IL-17+), Treg (CD4+CD25+CD127-) and cytotoxic (CD3+CD8+) in patients with vivax malaria and healthy controls after lymphocyte culture previously isolated from peripheral blood, to verify the change in the number of these subpopulations lymphocytes by infection with P. vivax. The percentage of IL-10 was also evaluated on Treg cells (CD4+CD25+CD127+IL-10). Individuals infected with P. vivax showed increased percentage of Th1 and cytotoxic T cells. The percentage of Th2, Th17 and Treg cells did not differ between groups. However, the percentage of Treg cells that produce IL-10 cytokine was increased in patients with vivax malaria compared to healthy controls. Finally, the evaluation of the number of CD4+ T and CD8+ T cells indicated that there were no differences between the proportion of these lymphocytes in healthy controls or during the infectious process induced by P. vivax. In conclusion, vivax malaria patients show an increase in the number of cytotoxic T cell, Th1 and Treg cells (CD4+CD25+CD127-) producers of interleukin-10, indicating that infection with P. vivax activate specific cells which can participate in the immunoregulation against this parasite.